13 results on '"Kala Jayaram"'
Search Results
2. P338: Objectives and design of the Acorn Study: A non-interventional study evaluating long-term safety in achondroplasia patients treated with vosoritide
- Author
-
Jeanne Pimenta, Shelda Cohen, Swati Mukherjee, Fiona Fettes, Kala Jayaram, and Ekkehart Lausch
- Subjects
Genetics ,QH426-470 ,Medicine - Published
- 2023
- Full Text
- View/download PDF
3. A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease
- Author
-
Barry J. Byrne, Tarekegn Geberhiwot, Bruce A. Barshop, Richard Barohn, Derralynn Hughes, Drago Bratkovic, Claude Desnuelle, Pascal Laforet, Eugen Mengel, Mark Roberts, Peter Haroldsen, Kristin Reilley, Kala Jayaram, Ke Yang, Liron Walsh, and on behalf of the POM-001/002 Investigators
- Subjects
Reveglucosidase alfa ,Late-onset Pompe disease ,Enzyme replacement therapy ,Pharmacokinetics ,Safety ,Efficacy ,Medicine - Abstract
Abstract Background Late-onset Pompe disease is a rare genetic neuromuscular disorder caused by lysosomal acid alpha-glucosidase (GAA) deficiency that ultimately results in mobility loss and respiratory failure. Current enzyme replacement therapy with recombinant human (rh)GAA has demonstrated efficacy in subjects with late-onset Pompe disease. However, long-term effects of rhGAA on pulmonary function have not been observed, likely related to inefficient delivery of rhGAA to skeletal muscle lysosomes and associated deficits in the central nervous system. To address this limitation, reveglucosidase alfa, a novel insulin-like growth factor 2 (IGF2)-tagged GAA analogue with improved lysosomal uptake, was developed. This study evaluated the pharmacokinetics, safety, and exploratory efficacy of reveglucosidase alfa in 22 subjects with late-onset Pompe disease who were previously untreated with rhGAA. Results Reveglucosidase alfa plasma concentrations increased linearly with dose, and the elimination half-life was
- Published
- 2017
- Full Text
- View/download PDF
4. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
- Author
-
Margareth C, Ozelo, Johnny, Mahlangu, K John, Pasi, Adam, Giermasz, Andrew D, Leavitt, Michael, Laffan, Emily, Symington, Doris V, Quon, Jiaan-Der, Wang, Kathelijne, Peerlinck, Steven W, Pipe, Bella, Madan, Nigel S, Key, Glenn F, Pierce, Brian, O'Mahony, Radoslaw, Kaczmarek, Joshua, Henshaw, Adebayo, Lawal, Kala, Jayaram, Mei, Huang, Xinqun, Yang, Wing Y, Wong, Benjamin, Kim, and Annette, Von Drygalski
- Subjects
Adult ,Male ,GENEr8-1 Trial Group ,Factor VIII ,Genetic Vectors ,Alanine Transaminase ,Hemorrhage ,Genetic Therapy ,General Medicine ,Dependovirus ,Hemophilia A ,Intention to Treat Analysis ,HIV Seronegativity ,General & Internal Medicine ,Humans ,Infusions, Intravenous ,11 Medical and Health Sciences - Abstract
BACKGROUND: Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) is an adeno-associated virus 5 (AAV5)-based gene-therapy vector containing a coagulation factor VIII complementary DNA driven by a liver-selective promoter. The efficacy and safety of the therapy were previously evaluated in men with severe hemophilia A in a phase 1-2 dose-escalation study. METHODS: We conducted an open-label, single-group, multicenter, phase 3 study to evaluate the efficacy and safety of valoctocogene roxaparvovec in men with severe hemophilia A, defined as a factor VIII level of 1 IU per deciliter or lower. Participants who were at least 18 years of age and did not have preexisting anti-AAV5 antibodies or a history of development of factor VIII inhibitors and who had been receiving prophylaxis with factor VIII concentrate received a single infusion of 6×1013 vector genomes of valoctocogene roxaparvovec per kilogram of body weight. The primary end point was the change from baseline in factor VIII activity (measured with a chromogenic substrate assay) during weeks 49 through 52 after infusion. Secondary end points included the change in annualized factor VIII concentrate use and bleeding rates. Safety was assessed as adverse events and laboratory test results. RESULTS: Overall, 134 participants received an infusion and completed more than 51 weeks of follow-up. Among the 132 human immunodeficiency virus-negative participants, the mean factor VIII activity level at weeks 49 through 52 had increased by 41.9 IU per deciliter (95% confidence interval [CI], 34.1 to 49.7; P
- Published
- 2022
- Full Text
- View/download PDF
5. Pharmacokinetics and Exposure–Response of Vosoritide in Children with Achondroplasia
- Author
-
Yulan Qi, Alice Huntsman-Labed, Carlos A. Bacino, Keiichi Ozono, Jonathan Day, Klaus Mohnike, Melita Irving, William R. Wilcox, Anu Cherukuri, Ming Liang Chan, Julie Hoover-Fong, Elena Fisheleva, William A. Horton, Kevin Larimore, Ravi Savarirayan, Lori Seid, Kala Jayaram, Joshua Henshaw, and George Jeha
- Subjects
medicine.medical_specialty ,Adolescent ,medicine.drug_class ,Injections, Subcutaneous ,Urinary system ,Diastole ,Cmax ,Achondroplasia ,Double-Blind Method ,Pharmacokinetics ,Internal medicine ,Heart rate ,Natriuretic peptide ,medicine ,Humans ,Pharmacology (medical) ,Child ,Vosoritide ,Pharmacology ,business.industry ,Natriuretic Peptide, C-Type ,medicine.disease ,Endocrinology ,Area Under Curve ,Child, Preschool ,business ,Biomarkers - Abstract
Vosoritide, an analog of C-type natriuretic peptide, has been developed for the treatment of children with achondroplasia. The pharmacokinetics of vosoritide and relationships between plasma exposure and efficacy, biomarkers, and safety endpoints were evaluated in a phase II, open-label, dose-escalation study (N = 35 patients aged 5–14 years who received daily subcutaneous injections for 24 months) and a phase III, double-blind, placebo-controlled study (N = 60 patients aged 5–18 years randomized to receive daily subcutaneous injections for 52 weeks). Pharmacokinetic parameters for both studies were obtained from non-compartmental analysis. Potential correlations between vosoritide exposure and changes in annualized growth velocity, collagen type X marker (CXM; a biomarker of endochondral ossification), cyclic guanosine monophosphate (cGMP; a biomarker of pharmacological activity), heart rate, and systolic and diastolic blood pressures were then evaluated. The exposure–response relationships for changes in both annualized growth velocity and the CXM biomarker saturated at 15 μg/kg, while systemic pharmacological activity, as measured by urinary cGMP, was near maximal or saturated at exposures obtained at the highest dose studied (i.e. 30 μg/kg). This suggested that the additional bioactivity was likely in tissues not related to endochondral bone formation. In the phase III study, following subcutaneous administration at the recommended dose of 15 μg/kg to patients with achondroplasia aged 5–18 years, vosoritide was rapidly absorbed with a median time to maximal plasma concentration (Cmax) of 15 minutes, and cleared with a mean half-life of 27.9 minutes after 52 weeks of treatment. Vosoritide exposure (Cmax and area under the concentration-time curve [AUC]) was consistent across visits. No evidence of accumulation with once-daily dosing was observed. Total anti-vosoritide antibody (TAb) responses were detected in the serum of 25 of 60 (42%) treated patients in the phase III study, with no apparent impact of TAb development noted on annualized growth velocity or vosoritide exposure. Across the exposure range obtained with 15 µg/kg in the phase III study, no meaningful correlations between vosoritide plasma exposure and changes in annualized growth velocity or CXM, or changes from predose heart rate, and systolic or diastolic blood pressures were observed. The results support the recommended dose of vosoritide 15 µg/kg for once-daily subcutaneous administration in patients with achondroplasia aged ≥ 5 years whose epiphyses are not closed. NCT02055157, NCT03197766, and NCT01603095.
- Published
- 2021
- Full Text
- View/download PDF
6. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study
- Author
-
Howard M. Saal, Carlos A. Bacino, Klaus Mohnike, Daniel Hoernschemeyer, Paul Harmatz, Yumiko Kotani, Julie Hoover-Fong, Jonathan Day, Frank Rutsch, Keiichi Ozono, Alice Huntsman-Labed, Joel Charrow, Rosendo Ullot Font, Elena Fisheleva, Antonio Leiva-Gea, Felipe Luna-González, Donald Basel, Natsuo Yasui, Lynda E. Polgreen, Kala Jayaram, Hiroshi Mochizuki, Ravi Savarirayan, Ignacio Ginebreda, Louise Tofts, Paul Arundel, Michael B. Bober, William R. Wilcox, Yasemin Alanay, Klane K. White, Melita Irving, Dania M Porco, and Acibadem University Dspace
- Subjects
Pediatrics ,medicine.medical_specialty ,Clinical Trials and Supportive Activities ,Clinical Sciences ,Brief Communication ,Placebo ,Achondroplasia ,Growth velocity ,Double-Blind Method ,Clinical Research ,Genetics ,medicine ,Humans ,Child ,Genetics (clinical) ,Vosoritide ,Pediatric ,Genetics & Heredity ,Growth promoting ,business.industry ,Extension study ,Natriuretic Peptide, C-Type ,medicine.disease ,Endochondral bone growth ,Treatment Outcome ,6.1 Pharmaceuticals ,Open label ,business ,General Economics, Econometrics and Finance - Abstract
Author(s): Savarirayan, Ravi; Tofts, Louise; Irving, Melita; Wilcox, William R; Bacino, Carlos A; Hoover-Fong, Julie; Font, Rosendo Ullot; Harmatz, Paul; Rutsch, Frank; Bober, Michael B; Polgreen, Lynda E; Ginebreda, Ignacio; Mohnike, Klaus; Charrow, Joel; Hoernschemeyer, Daniel; Ozono, Keiichi; Alanay, Yasemin; Arundel, Paul; Kotani, Yumiko; Yasui, Natsuo; White, Klane K; Saal, Howard M; Leiva-Gea, Antonio; Luna-Gonzalez, Felipe; Mochizuki, Hiroshi; Basel, Donald; Porco, Dania M; Jayaram, Kala; Fisheleva, Elena; Huntsman-Labed, Alice; Day, Jonathan RS | Abstract: PurposeAchondroplasia is caused by pathogenic variants in the fibroblast growth factor receptor 3 gene that lead to impaired endochondral ossification. Vosoritide, an analog of C-type natriuretic peptide, stimulates endochondral bone growth and is in development for the treatment of achondroplasia. This phase 3 extension study was conducted to document the efficacy and safety of continuous, daily vosoritide treatment in children with achondroplasia, and the two-year results are reported.MethodsAfter completing at least six months of a baseline observational growth study, and 52 weeks in a double-blind, placebo-controlled study, participants were eligible to continue treatment in an open-label extension study, where all participants received vosoritide at a dose of 15.0 μg/kg/day.ResultsIn children randomized to vosoritide, annualized growth velocity increased from 4.26 cm/year at baseline to 5.39 cm/year at 52 weeks and 5.52 cm/year at week 104. In children who crossed over from placebo to vosoritide in the extension study, annualized growth velocity increased from 3.81 cm/year at week 52 to 5.43 cm/year at week 104. No new adverse effects of vosoritide were detected.ConclusionVosoritide treatment has safe and persistent growth-promoting effects in children with achondroplasia treated daily for two years.
- Published
- 2022
- Full Text
- View/download PDF
7. Vosoritide treatment accelerates bone growth in children with achondroplasia
- Author
-
Alice Huntsman-Labed, George S Jeha, Jonathan Day, Antonio Leiva-Gea, Elena Fisheleva, Chandler Crews, Ravi Savarirayan, Keiichi Ozono, Kala Jayaram, Klaus Mohnike, Julie Hoover-Fong, Carlos A Bacino, Valerie Cormier-Daire, Yasemin Alanay, Melita Irving, Mary Andrews, and Cristina Klafehn
- Subjects
musculoskeletal diseases ,Bone growth ,medicine.medical_specialty ,Endocrinology ,business.industry ,Internal medicine ,medicine ,Achondroplasia ,business ,medicine.disease ,Vosoritide - Abstract
Vosoritide is a drug developed for the treatment of achondroplasia and has demonstrated increases in the growth velocity of children with this condition. Achondroplasia is a skeletal dysplasia (a condition affecting children’s bones and joints meaning they do not grow in the typical way) and is also referred to as dwarfism. There are currently no approved treatments for achondroplasia, except for growth hormone in Japan. When a new drug is being developed, it is essential to conduct clinical studies after many other steps to assess how well the drug works and whether it has any side effects. These studies of new drugs are carried out before the drug is approved to treat, improve, or reduce physical problems of certain conditions. This summary reports the results from two clinical studies looking at vosoritide as a potential treatment for children with achondroplasia. Study A compared different doses of vosoritide to find out which is the safest and shows the best results with the fewest side effects. Study B looked at how well vosoritide works compared with a nonactive medicine (known as a placebo) and the side effects. In these studies, vosoritide increased bone growth velocity in children with achondroplasia. Children receiving the drug every day generally only had mild side effects. Serious health conplications were generally medical events seen in children with achondroplasia even if they do not take vosoritide. No children stopped taking vosoritide during the studies due to safety reasons. How well vosoritide works and the side effects in children over a longer period of time are still being studied. ClinicalTrials.gov NCT numbers: NCT02055157 and NCT03197766 .
- Published
- 2021
- Full Text
- View/download PDF
8. Persistent and Stable Growth Promoting Effects of Vosoritide in Children With Achondroplasia for up to 2 Years: Results From the Ongoing Phase 3 Extension Study
- Author
-
Paul Arundel, Lynda E. Polgreen, Michael B. Bober, Ignacio Ginebreda, Ravi Savarirayan, Antonio Leiva-Gea, Louise Tofts, Hiroshi Mochizuki, Elena Fisheleva, Julie Hoover-Fong, Shoji Kagami, Kala Jayaram, Lynn Han, Dania M Porco, William R. Wilcox, Yasemin Alanay, Frank Rutsch, Howard M. Saal, Natsuo Yasui, Carlos A. Bacino, Klaus Mohnike, Donald Basel, Joel Charrow, Jonathan Day, Keiichi Ozono, Felipe Luna-González, Melita Irving, Rosendo Ullot Font, Daniel Hoernschemeyer, Paul Harmatz, and Klane K. White
- Subjects
Pediatrics ,medicine.medical_specialty ,Growth promoting ,business.industry ,Emerging Endocrine Therapies Across the Lifespan ,Endocrinology, Diabetes and Metabolism ,Extension study ,medicine.disease ,Phase (combat) ,Pediatric Endocrinology ,medicine ,Achondroplasia ,business ,AcademicSubjects/MED00250 ,Vosoritide - Abstract
Objectives: Vosoritide is a potent stimulator of endochondral bone growth and is in development for the treatment of achondroplasia, the most common form of disproportionate short stature. We previously reported on a 52-week, phase 3, pivotal study that demonstrated a highly statistically significant improvement in annualized growth velocity (AGV) when vosoritide was compared to placebo in children with achondroplasia aged 5-18 years (Savarirayan et al, Lancet, 2020). This is an analysis of data after an additional 52 weeks of treatment in the ongoing phase 3 extension study. Methods: After completion of the phase 3 placebo-controlled study, 119 children were enrolled into the extension study, where they all receive open label 15 μg/kg/day vosoritide. AGV, height Z-score and body proportion ratio were analyzed to assess efficacy of vosoritide in children who were treated with vosoritide for up to 2 years. Fifty-eight continued treatment with vosoritide and 61 switched from placebo to vosoritide. Two participants on continuous vosoritide treatment discontinued before the Week 52 timepoint. Four participants on continuous vosoritide treatment and 7 participants who switched from placebo to vosoritide missed the Week 52 assessment due to Covid-19. Results: In children randomized to receive daily vosoritide, baseline mean (SD) AGV was 4.26 (1.53) cm/year. After the first 52 weeks of treatment, mean (SD) AGV was 5.67 (0.98) cm/year. Mean (SD) AGV over the second year was 5.57 (1.10) cm/year. Mean (SD) change from baseline in height Z-score improved by +0.24 (0.31) at Week 52 in the pivotal study and +0.45 (0.56) at Week 52 in the extension study. Mean (SD) upper-to-lower body segment ratio improved with a change from baseline of -0.03 (0.11) at Week 52 in the pivotal study and -0.09 (0.11) at Week 52 in the extension study. In children who switched from placebo to vosoritide after 52 weeks, baseline AGV was 4.06 (1.20) cm/year and 3.94 (1.07) cm/year after 52 weeks on placebo. In the second year, after receiving 52 weeks of vosoritide, mean AGV was 5.65 (1.47) cm/year, the mean (SD) change in height Z-score was +0.24 (0.34), and the change in upper-to-lower body segment ratio was -0.03 (0.08). No new adverse events associated with vosoritide treatment were detected with up to 2 years of continuous daily, subcutaneous treatment. Most adverse events were mild and no serious adverse events were attributed to vosoritide. The most common adverse event remains mild and transient injection site reactions. Conclusions: The effect of vosoritide administration on growth as measured through AGV and height Z-score was maintained for up to 2-years in children with achondroplasia aged 5 to 18 years, with an improvement of body proportions.
- Published
- 2021
9. C-Type natriuretic peptide analogue therapy in children with achondroplasia
- Author
-
Anu Cherukuri, Ming Liang Chan, Alice Huntsman Labed, Kala Jayaram, Kim Hanh Le Quan Sang, Carlos A. Bacino, Joel Charrow, Kevin Larimore, George Jeha, Jonathan Day, Natalie N. Owen, Bret L. Bostwick, Ravi Savarirayan, Valérie Cormier-Daire, Julie Hoover-Fong, Melita Irving, Paul Harmatz, Patricia I. Dickson, and John A. Phillips
- Subjects
musculoskeletal diseases ,Male ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Adolescent ,Body height ,medicine.drug_class ,Injections, Subcutaneous ,Growth ,030204 cardiovascular system & hematology ,Short stature ,Achondroplasia ,03 medical and health sciences ,0302 clinical medicine ,Osteogenesis ,Internal medicine ,Natriuretic peptide ,medicine ,Humans ,030212 general & internal medicine ,Growth Charts ,Child ,Endochondral ossification ,Cyclic GMP ,Dose-Response Relationship, Drug ,business.industry ,Genetic disorder ,Natriuretic Peptide, C-Type ,General Medicine ,medicine.disease ,Body Height ,Endocrinology ,C-type natriuretic peptide ,Dysplasia ,Child, Preschool ,Female ,Collagen ,medicine.symptom ,business ,Biomarkers - Abstract
Achondroplasia is a genetic disorder that inhibits endochondral ossification, resulting in disproportionate short stature and clinically significant medical complications. Vosoritide is a biologic analogue of C-type natriuretic peptide, a potent stimulator of endochondral ossification.In a multinational, phase 2, dose-finding study and extension study, we evaluated the safety and side-effect profile of vosoritide in children (5 to 14 years of age) with achondroplasia. A total of 35 children were enrolled in four sequential cohorts to receive vosoritide at a once-daily subcutaneous dose of 2.5 μg per kilogram of body weight (8 patients in cohort 1), 7.5 μg per kilogram (8 patients in cohort 2), 15.0 μg per kilogram (10 patients in cohort 3), or 30.0 μg per kilogram (9 patients in cohort 4). After 6 months, the dose in cohort 1 was increased to 7.5 μg per kilogram and then to 15.0 μg per kilogram, and in cohort 2, the dose was increased to 15.0 μg per kilogram; the patients in cohorts 3 and 4 continued to receive their initial doses. At the time of data cutoff, the 24-month dose-finding study had been completed, and 30 patients had been enrolled in an ongoing long-term extension study; the median duration of follow-up across both studies was 42 months.During the treatment periods in the dose-finding and extension studies, adverse events occurred in 35 of 35 patients (100%), and serious adverse events occurred in 4 of 35 patients (11%). Therapy was discontinued in 6 patients (in 1 because of an adverse event). During the first 6 months of treatment, a dose-dependent increase in the annualized growth velocity was observed with vosoritide up to a dose of 15.0 μg per kilogram, and a sustained increase in the annualized growth velocity was observed at doses of 15.0 and 30.0 μg per kilogram for up to 42 months.In children with achondroplasia, once-daily subcutaneous administration of vosoritide was associated with a side-effect profile that appeared generally mild. Treatment resulted in a sustained increase in the annualized growth velocity for up to 42 months. (Funded by BioMarin Pharmaceutical; ClinicalTrials.gov numbers, NCT01603095, NCT02055157, and NCT02724228.).
- Published
- 2020
- Full Text
- View/download PDF
10. SAT-LB18 A Randomized Controlled Trial of Vosoritide in Children With Achondroplasia
- Author
-
Klane K. White, Felipe Luna-Gonzáles, Antonio Leiva-Gea, Lynda E. Polgreen, Rosendo Ullot Font, Alice Huntsman-Labed, Donald Basel, Natsuo Yasui, Dania M Porco, Jonathan Day, Elena Fisheleva, Hiroshi Mochizuki, Melita Irving, Paul Harmatz, Keiichi Ozono, Daniel Hoernschmeyer, Yasemin Alanay, Julie Hoover-Fong, Joel Charrow, Kala Jayaram, Howard M. Saal, Frank Rutsch, Carlos A. Bacino, Klaus Mohnike, Ignacio Ginebreda, Paul Arundel, William R. Wilcox, Michael B. Bober, Ravi Savarirayan, Louise Tofts, and Shoji Kagami
- Subjects
Pediatrics ,medicine.medical_specialty ,business.industry ,Endocrinology, Diabetes and Metabolism ,medicine.disease ,law.invention ,Randomized controlled trial ,Pediatric Endocrinology ,law ,medicine ,Pediatric Growth and Adrenal Disorders ,Achondroplasia ,business ,AcademicSubjects/MED00250 ,Vosoritide - Abstract
Background: Achondroplasia is a disorder caused by specific mutations in the gene encoding the fibroblast growth factor receptor 3 (FGFR3) protein. Open-label, phase 2 trials in children with achondroplasia showed that administration of vosoritide, an analogue of C-natriuretic peptide, resulted in sustained increases in annualized growth velocity. Methods: This international, randomized, double-blind, phase 3 trial compared once-daily subcutaneous administration of vosoritide, at a dose of 15 μg per kg of body weight, with placebo in children with achondroplasia aged 5 to
- Published
- 2020
11. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial
- Author
-
Melita Irving, Klane K. White, Louise Tofts, Yasemin Alanay, Joel Charrow, Felipe Luna-González, William R. Wilcox, Frank Rutsch, Alice Huntsman-Labed, Paul Arundel, Dania M Porco, Lynda E. Polgreen, Michael B. Bober, Howard M. Saal, Daniel Hoernschemeyer, Carlos A. Bacino, Donald Basel, Elena Fisheleva, Shoji Kagami, Paul Harmatz, Jonathan Day, Klaus Mohnike, Rosendo Ullot Font, Keiichi Ozono, Julie Hoover-Fong, Kala Jayaram, Ignacio Ginebreda, Ravi Savarirayan, Hiroshi Mochizuki, Antonio Leiva-Gea, and Natsuo Yasui
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Injections, Subcutaneous ,030204 cardiovascular system & hematology ,Placebo ,Achondroplasia ,Growth velocity ,Double blind ,03 medical and health sciences ,0302 clinical medicine ,Absorptiometry, Photon ,Double-Blind Method ,Bone Density ,Osteogenesis ,Clinical endpoint ,medicine ,Humans ,030212 general & internal medicine ,Child ,Vosoritide ,business.industry ,Natriuretic Peptide, C-Type ,General Medicine ,medicine.disease ,Body Height ,Injection Site Reaction ,Child, Preschool ,Ambulatory ,Female ,Once daily ,business ,Biomarkers ,Collagen Type X - Abstract
BACKGROUND: There are no effective therapies for achondroplasia. An open-label study suggested that vosoritide administration might increase growth velocity in children with achondroplasia. This phase 3 trial was designed to further assess these preliminary findings. METHODS: This randomised, double-blind, phase 3, placebo-controlled, multicentre trial compared once-daily subcutaneous administration of vosoritide with placebo in children with achondroplasia. The trial was done in hospitals at 24 sites in seven countries (Australia, Germany, Japan, Spain, Turkey, the USA, and the UK). Eligible patients had a clinical diagnosis of achondroplasia, were ambulatory, had participated for 6 months in a baseline growth study and were aged 5 to less than 18 years at enrolment. Randomisation was done by means of a voice or web-response system, stratified according to sex and Tanner stage. Participants, investigators, and trial sponsor were masked to group assignment. Participants received either vosoritide 15·0 µg/kg or placebo, as allocated, for the duration of the 52-week treatment period administered by daily subcutaneous injections in their homes by trained caregivers. The primary endpoint was change from baseline in mean annualised growth velocity at 52 weeks in treated patients as compared with controls. All randomly assigned patients were included in the efficacy analyses (n=121). All patients who received one dose of vosoritide or placebo (n=121) were included in the safety analyses. The trial is complete and is registered, with EudraCT, number, 2015-003836-11. FINDINGS: All participants were recruited from Dec 12, 2016, to Nov 7, 2018, with 60 assigned to receive vosoritide and 61 to receive placebo. Of 124 patients screened for eligibility, 121 patients were randomly assigned, and 119 patients completed the 52-week trial. The adjusted mean difference in annualised growth velocity between patients in the vosoritide group and placebo group was 1·57 cm/year in favour of vosoritide (95% CI [1·22-1·93]; two-sided p
- Published
- 2020
12. Vosoritide for children with achondroplasia: a 60-month update from an ongoing phase 2 clinical trial
- Author
-
Melita Irving, Valérie Cormier-Daire, Paul Harmatz, Patricia I. Dickson, Elena Fisheleva, Joel Charrow, Julie Hoover-Fong, John D. Phillips, Kala Jayaram, Alice Huntsman Labed, Ravi Savarirayan, Jonathan Day, Lynda E. Polgreen, George Jeha, Carlos A. Bacino, and Kevin Larimore
- Subjects
Pediatrics ,medicine.medical_specialty ,business.industry ,Endocrinology, Diabetes and Metabolism ,Phases of clinical research ,medicine.disease ,Biochemistry ,Endocrinology ,Genetics ,medicine ,Achondroplasia ,business ,Molecular Biology ,Vosoritide - Published
- 2021
- Full Text
- View/download PDF
13. Vector Shedding and Blood Biodistribution in Patients with Severe Hemophilia a Following Administration of Valoctocogene Roxaparvovec
- Author
-
Kevin Hammon, Benjamin Kim, Chris B. Russell, Annie Clark, Joshua Henshaw, Jennifer Holcomb, Kala Jayaram, Elli Koziol, Krystal Sandza, Christian Vettermann, and Richard Torres
- Subjects
Saliva ,business.industry ,Immunology ,Semen ,Cell Biology ,Hematology ,Biochemistry ,Virology ,Peripheral blood mononuclear cell ,Virus ,Transduction (genetics) ,chemistry.chemical_compound ,chemistry ,Medicine ,Vector (molecular biology) ,business ,DNA ,Whole blood - Abstract
Introduction: Long-term durable expression of hFVIII-SQ has been observed following BMN 270 (AAV5-hFVIII-SQ, valoctocogene roxaparvovec) single-dose administration in patients with severe hemophilia A. Although adeno-associated virus (AAV) vectors are replication incompetent and thus pose minimal risk for transmission or release into environment, a comprehensive assessment of vector shedding in secreta and excreta is required as part of the clinical development program. In addition, evaluation of vector biodistribution in blood is useful to characterize vector DNA processing and further understand the kinetics of vector DNA clearance. Vector shedding and biodistribution were evaluated from subjects from an ongoing Phase 1/2 study (Study 270-201, NCT02576795) and an ongoing Phase 3 study (Study 270-301, NCT03370913) following BMN 270 administration in patients with severe hemophilia A. Methods: In the Phase 1/2 study, 15 adult male subjects with severe hemophilia A received a single intravenous infusion of 6E12 vg/kg (n=1), 2E13 vg/kg (n=1), 4E13 vg/kg (n=6), or 6E13 vg/kg (n=7) BMN 270. In the Phase 3 study, 134 adult male subjects with severe hemophilia A received a single intravenous infusion of 6E13 vg/kg BMN 270. In both studies, measurement of vector DNA in blood, saliva, feces, semen, and urine was performed using a validated qPCR assay. Blood, saliva, urine, stool, and semen were collected until at least 3 consecutive negative results via qPCR were obtained. To further characterize vector DNA potentially capable of cell transduction, a novel immunocapture qPCR (iqPCR) assay was developed to measure the amount of intact AAV5 vector capsids in plasma and semen. Further assessments of the biodistribution of vector DNA in blood, including the evaluation of the contiguity and structural characteristics of BMN 270 vector genomes, were performed in blood, plasma, peripheral blood mononuclear cells (PBMC), and red blood cells using a drop-phase droplet-digital (dd)PCR assay. Results: Following BMN 270 administration at all dose levels, vector DNA was detected in all subjects in all biodistribution and shedding matrices evaluated (i.e., blood, saliva, urine, stool, and semen). Median peak vector DNA levels were greatest in blood followed by saliva, semen, stool, and urine. Peak vector DNA concentrations following BMN 270 administration were observed early. Following peak vector DNA concentrations, BMN 270 vector genomes were steadily cleared from the urine, semen, saliva, stool, and blood. In comparison to total vector DNA measured by qPCR, encapsidated vector DNA in plasma and semen was cleared more rapidly, as measured using iqPCR. Evaluation of total vector DNA in whole blood and blood fractions, indicate 3 phases of vector DNA clearance, which are associated with the expected lifespan of various transduced cell types. From approximately 24 weeks after BMN 270 administration and beyond, a slower rate of decline of vector DNA in whole blood is observed with the majority of transgene DNA present beyond 24 weeks in blood likely within the PBMC fraction. Further characterization of vector DNA in blood demonstrated that BMN 270 DNA transitioned from an initial truncated form into full-length transgenes over time. In addition, the fraction of DNA detected in whole blood that contains an inverted terminal repeat (ITR) fusion, indicating that the residual vector DNA may have formed circular episomes in the transduced cells, increased over time. By 52 weeks post-BMN 270 administration, the majority of vector DNA in whole blood was full-length and contained an ITR fusion. Conclusions: Vector shedding and distribution has been extensively evaluated in patients with severe hemophilia A treated with BMN 270. Both vector DNA and vector capsids were detected and steadily cleared in blood and shedding matrices. Based upon the replication incompetent nature of BMN 270 and the maximum potential exposure to the vector in secreta and excreta following BMN 270 administration, the risk of transmission to untreated individuals is considered extremely low. The biodistribution and characterization of vector DNA in blood cells demonstrates the formation of full-length transgenes with ITR fusions. Disclosures Clark: BioMarin Pharmaceutical In.: Current Employment. Hammon:BioMarin Pharmaceutical Inc.: Current Employment. Sandza:BioMarin Pharmaceutical Inc.: Current Employment. Torres:BioMarin Pharmaceutical Inc.: Current Employment. Koziol:BioMarin Pharmaceutical Inc.: Current Employment. Holcomb:BioMarin Pharmaceutical Inc.: Current Employment. Kim:BioMarin Pharmaceutical Inc.: Current Employment. Jayaram:BioMarin Pharmaceutical Inc.: Current Employment. Russell:BioMarin Pharmaceutical Inc.: Current Employment, Current equity holder in publicly-traded company; Amgen nc.: Current equity holder in publicly-traded company, Ended employment in the past 24 months. Vettermann:BioMarin Pharmaceutical Inc.: Current Employment. Henshaw:BioMarin Pharmaceutical Inc.: Current Employment.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.